Cargando…

Real-world study of bevacizumab treatment in patients with ovarian cancer: a Chinese single-institution study of 155 patients

OBJECTIVE: The purpose of this study was to retrospectively assess the pattern, compliance, efficacy and safety of bevacizumab in Chinese ovarian cancer patients. METHODS: We reviewed the clinicopathological data of patients with histologically confirmed epithelial ovarian cancer, fallopian tube can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Nan, Zheng, Hong, Gao, Yunong, Shu, Tong, Wang, Hongguo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10103494/ https://www.ncbi.nlm.nih.gov/pubmed/37055754 http://dx.doi.org/10.1186/s12905-023-02329-9

Ejemplares similares

Real-World Efficacy of Bevacizumab in Patients With Recurrent Epithelial Ovarian Cancer
por: Hung, Jo-Ni, et al.
Publicado: (2022)

Pemetrexed-Platinum With or Without Bevacizumab for Chinese Chemo-Naive Advanced Lung Adenocarcinoma Patients: A Real-World Study
por: Li, Xin, et al.
Publicado: (2021)

Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients
por: Patil, Pratik P., et al.
Publicado: (2021)

Austria-based real-world data on bevacizumab in newly diagnosed epithelial ovarian cancer
por: Tsibulak, Irina, et al.
Publicado: (2022)

Real world study of the continuation of bevacizumab beyond disease progression after first‐line treatment containing bevacizumab in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients
por: Berton, Dominique, et al.
Publicado: (2021)

Real world study of regimen containing bevacizumab as first‐line therapy in Chinese patients with advanced non‐small cell lung cancer
por: Xing, Puyuan, et al.
Publicado: (2018)

Real-world efficacy and safety of bevacizumab single-maintenance therapy following platinum-paclitaxel chemotherapy plus bevacizumab in patients with advanced cervical cancer
por: Kotaka, Saki, et al.
Publicado: (2023)

Effectiveness and Safety of Belimumab in Chinese Lupus Patients: A Multicenter, Real-World Observational Study
por: Sun, Fangfang, et al.
Publicado: (2023)

Real-world clinical experience of secukinumab in Chinese patients with psoriasis in real-world practice: a 36-week single-center study of 24 patients
por: Zhang, Jing, et al.
Publicado: (2020)

Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb)
por: Jin, Ran, et al.
Publicado: (2023)

Timing and duration of bevacizumab treatment and survival in patients with recurrent ovarian, fallopian tube, and peritoneal cancer: a multi-institution study
por: Ghezelayagh, Talayeh S., et al.
Publicado: (2023)

Real-World Study of Adding Bevacizumab to Chemotherapy for Ovarian, Tubal, and Peritoneal Cancer as Front-Line or Relapse Therapy (ROBOT): 8-Year Experience
por: Wu, Pei-Ying, et al.
Publicado: (2020)

Single‐institution retrospective review of patients with recurrent glioblastoma treated with bevacizumab in clinical practice
por: Desjardins, Annick, et al.
Publicado: (2019)

Real‐world data of chronic myelomonocytic leukemia: A chinese single‐center retrospective study
por: Ma, Liya, et al.
Publicado: (2021)

Safety Analysis of Bevacizumab in Ovarian Cancer Patients
por: Wang, Yingwen, et al.
Publicado: (2023)

Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian Cancer
por: Zheng, Hong, et al.
Publicado: (2021)

Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice
por: Dinu, Ioana Mihaela, et al.
Publicado: (2023)

Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients
por: Detti, Beatrice, et al.
Publicado: (2021)

Pazopanib in patients with metastatic renal cell carcinoma: a single-center, real-world, retrospective Chinese study
por: Chen, Jianhui, et al.
Publicado: (2021)

ToleRability of BevacizUmab in elderly Ovarian cancer patients (TURBO study): a case-control study of a real-life experience
por: Amadio, Giulia, et al.
Publicado: (2019)

Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution
por: Cerveira, Nuno, et al.
Publicado: (2018)

A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India
por: Sinha, Shubhadeep D, et al.
Publicado: (2023)

A real-world study of effectiveness of intravitreal bevacizumab and ranibizumab injection for treating retinal diseases in Thailand
por: Kumluang, Suthasinee, et al.
Publicado: (2019)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario
por: Jain, Prashant, et al.
Publicado: (2017)

BRCA Variants Do Not Increase the Risk of Adverse Reactions in Patients With Ovarian Cancer: A Single-Center Real-World Study
por: Li, Kemin, et al.
Publicado: (2022)

Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
por: Cheng, Wen-Chien, et al.
Publicado: (2023)

Chemotherapy for biliary tract cancer: real-world experience in a single institute
por: Maeda, Osamu, et al.
Publicado: (2020)

Real‐world clinical outcomes of olaparib therapy in Chinese patients with advanced serous ovarian cancer treated in Macau
por: Cao, Yabing, et al.
Publicado: (2019)

Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients
por: Wang, Yang, et al.
Publicado: (2012)

Gastrointestinal perforation after bevacizumab: a multi-site, single-institution study with a focus on survival
por: Storandt, Michael H., et al.
Publicado: (2023)

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
por: Ando, Yuwa, et al.
Publicado: (2021)

Incidence of fistula occurrence in patients with cervical cancer treated with bevacizumab: data from real-world clinical practice
por: Sugiyama, Toru, et al.
Publicado: (2022)

Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer
por: Arrichiello, Gianluca, et al.
Publicado: (2022)

Bevacizumab in the treatment of ovarian cancer
por: Eskander, Ramez N, et al.
Publicado: (2011)

Real-World Safety of Intravitreal Bevacizumab and Ranibizumab Treatments for Retinal Diseases in Thailand: A Prospective Observational Study
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2018)

A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer
por: Sugiyama, Toru, et al.
Publicado: (2017)

Efficacy and safety of lapatinib in Chinese breast cancer patients: a real-world study
por: Ye, Xuan, et al.
Publicado: (2020)

Efficacy and Safety of Dupilumab in Chinese Patients With Atopic Dermatitis: A Real-World Study
por: Zhou, Bingjing, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_r0dc15v53h6ssp6db24ejnsn2i